Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein

Min Zhang1†, Jin Shen2†, Shuizhen Zhou1, Xiaonan Du1, Wenhui Li1, Lifei Yu1, Yunjian Zhang1, Yi Wang1 and Linmei Zhang1*

1 Department of Neurology, Children’s Hospital of Fudan University, Shanghai, China, 2 Department of Radiology, Children’s Hospital of Fudan University, Shanghai, China

Objective: To compare the clinical and neuroimaging characteristics of anti-myelin oligodendrocyte glycoprotein antibody (MOG-ab) negative and positive pediatric acute disseminating encephalomyelitis (ADEM) patients.

Methods: Clinical characteristics, neuroimaging features, ancillary examination results, and outcomes of pediatric ADEM patients were retrospectively reviewed between February 2016 and July 2019.

Results: Among 37 pediatric ADEM patients, 24 patients (11 girls and 13 boys) fulfilled the inclusion criteria. The median age was 72 (range 19–156) months, and the median follow-up duration was 20 (range 12–48) months. Children with ADEM and MOG-abs presented with increased ataxia, reduced bladder/rectum dysfunction, and paralysis compared to children without MOG-abs. An important finding was that no significant differences existed in age at symptom onset, sex ratio, time from immunotherapy to clinical improvement and clinical recovery, or modified Rankin Scale (mRS) at the last follow-up. More typical cerebral MRI lesions were detected in patients with ADEM and MOG-abs than in children without MOG-abs [11/12 (91.7%) vs. 8/12 (66.7%)]. Cerebellar lesions were higher in ADEM patients with MOG-abs (7/12, 58.3%) than in those without MOG-abs (2/12, 16.7%). While seven children had abnormal spinal MRI findings (7/12, 58.3%) and five had longitudinally extensive transverse myelitis (LETM) (5/12, 41.7%) per group, the coexistence of spinal dysfunction and abnormal spinal MRI was lower in ADEM with MOG-abs (2/12, 16.7%) than in children without MOG- abs (7/12, 58.3%). Clinical improvement was achieved 1 week after immunotherapy. Most children in both groups achieved clinical recovery within 3 months after immunotherapy, although two (16.7%) patients with ADEM and MOG- abs had persistent neurological sequelae at the last follow-up.

Conclusion: MOG-abs-positive ADEM is a major subtype of pediatric ADEM. Ataxia is the most common clinical presentation in pediatric ADEM and MOG- abs. Children with ADEM and MOG- abs have similar patterns of lesions characterized by large,
bilateral, widespread lesions, as well as more cerebellar lesions than children without MOG-abs. Most spinal lesions were subclinical in pediatric ADEM with MOG-abs. A favorable prognosis can be achieved for pediatric ADEM regardless of the MOG-abs status. However, some patients with MOG-abs are likely to have more severe neurological sequelae.

Keywords: myelin oligodendrocyte glycoprotein antibody, MOG, Acute disseminating encephalomyelitis, pediatric, myelin oligodendrocyte glycoprotein, ADEM

INTRODUCTION

Acute disseminated encephalomyelitis (ADEM) is typically a monophasic inflammatory demyelinating disease characterized by polyfocal clinical symptoms, encephalopathy, and magnetic resonance imaging (MRI) findings consistent with demyelination. Cerebral MRI usually shows diffuse, poorly demarcated, and bilateral lesions most predominantly in cerebral white matter and the spinal cord (1). The estimated incidence of ADEM in children ranges between 0.2 and 0.4 per 100,000 (2, 3). In recent years, researches have indicated that serum immunoglobulin G (IgG) antibodies to myelin oligodendrocyte glycoprotein (MOG-abs) exist in approximately up to 40% of children with ADEM and in nearly 100% of children with multiphasic disseminated encephalomyelitis (MDEM) (4). ADEM commonly follows a monophasic course with a favorable prognosis, but a recent report published by Hennes et al. (5) suggested that 22 of 65 MOG-abs-positive children (33.8%) experienced a clinical relapse and were diagnosed with MDEM (6), recurrent optic neuritis (RON) (7), ADEM followed by optic neuritis (ADEM-ON) (8), or neuromyelitis optica spectrum disorders (NMOSDs) (9, 10). MOG-abs-associated disease (MOGAD) has become an important clinical phenotype associated with acquired demyelinating syndromes (ADSs). Previous studies have reported the clinical and neuroradiological differences of pediatric ADEM with positive MOG-abs (4, 5) and characteristics of relapsing MOGAD in Chinese children (11). However, thus far, differences in the clinical and neuroimaging characteristics of ADEM patients with and without MOG-abs in the Chinese pediatric population have not been delineated in literature.

Therefore, we retrospectively delineated the demographic and clinical characteristics, neuroimaging results, treatment, and clinical outcomes of pediatric ADEM with and without MOG-abs from a national children’s medical center in China.

MATERIALS AND METHODS

Patients

We retrospectively reviewed the medical records of all hospitalized patients who were diagnosed with previous ADSs such as ADEM, optic neuritis (ON), neuromyelitis optica (NMO), NMOSDs, transverse myelitis (TM), or clinically isolated syndrome (CIS). We obtained data from the electronic medical records system of the Children’s Hospital of Fudan University (Shanghai, China) between February 2016 and July 2019 when MOG-ab tests could be clinically used by fixed cell-based assays (CBAs). Thirty-seven patients were initially identified as fulfilling the diagnostic criteria for ADEM based on the International Pediatric Multiple Sclerosis Study Group (IPMSSG) recommendations, which include a first polyfocal central nervous system (CNS) event with a presumed inflammatory demyelinating cause, encephalopathy that cannot be explained by fever, systemic illness or postictal symptoms, and an abnormal cerebral MRI during the acute phase compatible with ADEM and not indicative of another CNS disease (1). Other inclusion criteria were (a) pediatric onset of symptoms (<18 years); (b) no history of ADSs such as ON, TM, or CIS; (c) complete medical records including demographic characteristics, clinical symptoms, cerebrospinal fluid (CSF) results, cerebral and spinal MRI images, electroencephalogram (EEG) results, serum anti-MOG and anti-aquaporin-4 (anti-AQP4) antibodies results, and all the results were obtained in the acute stage of disease (<3 months) before immunotherapy; and (d) follow-up period of ≥12 months. We excluded other definitive diagnoses that could be better explained by diseases such as viral encephalitis, bacterial meningitis, metabolic encephalopathy, autoimmune encephalitis, hypoxia, or poisons; besides, we excluded patients diagnosed with other demyelinating diseases during follow-up. Of the 37 patients identified with pediatric ADEM, 24 patients were ultimately included in this study (Figure 1).

We obtained the following information from each patient through a review of the electronic medical record system and/or telephone interviews: age at symptom onset, sex, clinical symptoms, previous infections, intensive care unit (ICU) admission, period of hospital stay, time from symptom onset to immunotherapy, time from immunotherapy to clinical improvement and clinical recovery, modified Rankin Scale (mRS) before immunotherapy and at the last follow-up, titers of anti-MOG-ab, CSF results [i.e., leukocyte count, protein levels, and/or oligoclonal bands (OCBs)], neuroimaging results, as well as treatment and clinical outcomes at the last follow-up. All administered treatments were first-line immunotherapies, including one or any combination of corticosteroid as well as intravenous immunoglobulin (IVIG) and plasma exchange (PE). Before immunotherapy, each patient received a lumbar puncture, a serum MOG-abs and AQP4-abs test, and a cerebral and spinal MRI.

Clinical symptoms were classified as altered consciousness, emotional/behavior disorders, seizures, ON, cranial nerve (III–XII) palsy, ataxia, sensory symptoms, bladder/rectum dysfunction, and paralysis. Clinical outcomes were evaluated
based on mRS before immunotherapy and during clinical visits to the neurologist or through a telephone interview after discharge. The evaluation standards were as follows: full recovery, mRS of 0; mild deficits, mRS of 1–2; severe deficits, mRS of 3–5; or death, mRS of 6 (12). We defined clinical improvement as an increase of 1 in mRS and clinical recovery as an mRS of 0–2. In view of the fact that clinical recovery is a step-by-step process that is difficult to pinpoint to a certain day, we divided the time from immunotherapy to clinical recovery into four time periods: ≤2 weeks, 2–4 weeks, 4 weeks–3 months, and ≥3 months. Recurrence was defined as the development of new symptoms at least 3 months after the illness incident, Irrespective of steroid use.

Serum Antibody Status of Myelin Oligodendrocyte Glycoprotein and Aquaporin 4

Before immunotherapy, all serum samples were tested for anti-MOG immunoglobulin [immunoglobulin G (IgG)] and anti-AQP4 IgG at the China branch of Euroimmun Medical Diagnostic Laboratory through a fixed cell-based indirect immunofluorescence test (IIFT) employing BIOCHIP (EUROIMMUN AG, Luebeck, Germany) before immunotherapy. Full-length human MOG and AQP4 isoform M1-transfected HEK293 cells were used in the anti-MOG and anti-AQP4 IIFT, respectively. Titer levels of ≥1:10 were classified as serum positive.

Neuroimaging

All patients received cerebral and spinal cord MRI with the Siemens Avanto 1.5T MRI unit (Siemens AG, Erlangen, Germany) or the GE750 Discovery 3T MRI unit (GE Healthcare, Waukesha, WI, USA). Cerebral MRI included axial T1, T2, T2 fluid-attenuated inversion recovery, diffusion-weighted and sagittal T1 images of the brain. Spinal cord MRI included sagittal T1, T2, T2 fat-suppressed and axial T2 fat-suppressed images of the spinal cord. Intravenous contrast was used in most patients. All MRI studies were evaluated by a radiologist and a senior pediatric neurologist (JS and LZ, respectively), who were blinded to the clinical diagnosis of the patients before immunotherapy, and by a third rater (SZ) in instances of discordant results. Cerebral and spinal lesion locations were the supratentorial white matter (e.g., juxtacortical, non-juxtacortical, and non-periventricular white matter, periventricular white matter, and corpus callosum), thalamus/basal ganglia, brainstem, cerebellum, or myelin with and without LETM (which was defined as spinal cord lesions extending over three or more vertebral levels on sagittal spinal MRI) (2). A typical cerebral MRI was defined as blurred/hazy, large (i.e., ≥2 cm on the axial sequence) lesions in the aforementioned anatomical locations (13).

Statistical Analysis

Statistical analysis was performed by using IBM SPSS, release v.20.0 (IBM Corporation). We compared demographic, clinical, neuroimaging, and serological data by the Kruskal–Wallis test, Mann–Whitney test, Wilcoxon rank test, Fisher’s exact test,
RESULTS

Clinical Characteristics

From a cohort of 37 children who fulfilled the diagnostic criteria for ADEM, 24 patients (11 girls and 13 boys) were enrolled. They had a median age of 72 (range 19–156) months and a median follow-up of 20 (range 12–48) months (Figure 1). The demographic and clinical characteristics, neuroimaging results, and clinical outcomes of the patients are summarized in Table 1. Fourteen (42.4%) of 33 patients who were tested for MOG-antibodies were recorded as positive. Patients positive for MOG-antibodies presented with significantly more ataxia (P = 0.025) and less bladder/rectum dysfunction (P = 0.035) and paralysis (P = 0.04) than patients without MOG-antibodies. In each group, seven [58.3% (7/12)] children had abnormal spinal MRI findings. All seven (100%) patients in the ADEM without MOG-antibodies group also had symptoms of myelitis. This percentage was significantly higher than that of the patients in the ADEM with MOG-antibodies group (2/7, 28.6%; P = 0.035). An important finding was that no significant difference existed between the two groups in age at symptom onset, sex ratio, length of hospital stay, previous infections, ICU admission, follow-up period, time from symptom onset to immunotherapy, time from immunotherapy to clinical improvement and clinical recovery, time from symptom onset to EEG recording, time from symptom onset to MRI, or mRS results at the last follow-up.

Ancillary Examination Results

All tested serum samples were obtained before immunotherapy. No significant differences existed in time from symptom onset to lumbar puncture or CSF white blood cell count and protein concentration between the ADEM groups with and without MOG-antibodies. Among patients who tested positive for OCBs, two (25.0%) of eight patients with MOG-antibodies and no patient without MOG-antibodies had unmatched OCBs in the CSF (P = 0.004).

Overall, 14 (42.4%) of 33 children who were tested for the presence of MOG-antibodies were positive. Anti-MOG-antibody titers ranged from 1:10 to 1:320 (six for 1:10, four for 1:32, one for 1:100, and one for 1:320). All patients tested negative for anti-AQP4 antibodies. Overall, 15 children were tested for anti-N-methyl-D-aspartate receptor (anti-NMDAR) antibodies in the serum and CSF (nine children were in the ADEM with MOG-antibodies group and six children were in the ADEM without MOG-antibodies group). Only one child in the ADEM with MOG-antibodies group was positive for anti-NMDAR antibodies in serum and CSF (1:320 in the serum and 1:32 in the CSF). However, the clinical presentation, cerebral MRI, clinical course, and prognosis were more in line with ADEM than with anti-NMDAR encephalitis (12). The median time from symptom onset to EEG recording was 25.5 (range: 4–57) days and 11.5 (range: 4–49) days in patients with MOG-antibodies and without MOG-antibodies, respectively. The most common EEG result was slow background activity, which was detected in seven (58.3%) of 12 children with MOG-antibodies and in 10 (83.3%) of 12 children without MOG-antibodies. However, no significant differences existed between the two groups.

MRI Findings

Neuroimaging results are shown in Figures 2, 3. Typical cerebral MRI lesions, which were defined as blurred/hazy, large (≥2 cm on the axial sequence) lesions, were recorded in 11 (91.7%) of 12 children with MOG-antibodies (Figures 2A,B) and in eight (66.7%) of 12 children without MOG-antibodies (Figures 3A,B). Supratentorial white matter (Figures 2A, 3A) and thalamus/basal ganglia lesions (Figures 2B, 3B) were the most common lesion locations across groups and affected 11 (91.7%) of 12 children with MOG-antibodies and 10 (83.3%) of 12 children without MOG-antibodies. In children with MOG-antibodies, lesions were detected in the following locations: brainstem (9/12 patients, 75.0%; Figure 2G), cerebellum (7/12 patients, 58.3%; Figure 2G), and spine (7/12 patients, 58.3%; Figures 2H, 3H). However, in children without MOG-antibodies, lesions were detected in the brainstem (4/12 patients, 33.3%; Figure 3F), cerebellum (2/12 patients, 16.7%; Figure 3G), and spine (7/12 patients, 58.3%; Figures 3H, J). Children with MOG-antibodies had a significantly higher number of cerebellar lesions (7/12, 58.3%) than did children without MOG-antibodies (2/12, 16.7%) (P = 0.045). Seven (58.3%) of 12 children from each group had abnormal spinal MRI findings. Among these seven children, LETM was detected in five (71.4%) children (Figures 2H, 3H). Only two (28.6%) of seven children in the ADEM with MOG-antibodies group presented with symptoms of myelopathy compared to all seven (100%) children in the ADEM without MOG-antibodies group (P = 0.035). Corpus callosum lesions were detected in four (33.3%) of 12 patients and in two (16.7%) of 12 patients with MOG-antibodies and without MOG-antibodies, respectively (Figures 2B, 3I). Other spinal lesions extending <3 vertebral levels on sagittal spinal MRI image or small flake lesions were also detected in ADEM patients with and without MOG-antibodies (Figure 3F).

Treatment and Outcomes

Twenty-one (87.5%) of 24 children were treated within 30 days of the first symptom onset. All (100%) ADEM patients positive for MOG-antibodies were treated with IVIG; nine (75%) patients were treated with intravenous methylprednisolone, followed by oral prednisone; and two (16.7%) patients were treated with oral prednisone only. However, among 12 ADEM patients negative for MOG-antibodies, 11 (91.7%) patients, eight (66.7%) patients, and three (25%) patients were treated with IVIG; intravenous methylprednisolone, followed by oral prednisone; and oral prednisone only, respectively. One (8.3%) child was treated with IVIG only in each group. The median time from immunotherapy to an improvement in clinical symptoms was 7 (range: 3–30) days in the ADEM with MOG-antibodies group and 8 (range: 4–30) days in the ADEM without MOG-antibodies group (P = 0.794). As mentioned previously, clinical outcomes were evaluated based on mRS. Higher mRS were recorded in the ADEM without MOG-antibodies group before immunotherapy (P = 0.01); however, no significant difference existed between the two groups at the last follow-up. Most [91.7% (11/12)] children in each group achieved clinical recovery within 3 months after immunotherapy. Ten (83.3%) of 12 children with ADEM and MOG-antibodies had a normal outcome.
|                      | MOG-IgG positive (n = 12) | MOG-IgG negative (n = 12) | P-value |
|----------------------|---------------------------|---------------------------|---------|
| Age at onset (months)| 69.5 (19–156)             | 84 (19–156)               | 0.664   |
| Females             | 6 (50%)                   | 5 (41.7%)                 | 0.682   |
| Symptoms             |                           |                           |         |
| Altered consciousness| 12 (100%)                 | 12 (100%)                 |         |
| Emotional/behavioral changes | 2 (16.7%)   | 2 (16.7%)                 | 1.000   |
| Seizures            | 2 (16.7%)                 | 3 (25%)                   | 0.615   |
| Optic neuritis      | 1 (8.3%)                  | 1 (8.3%)                  | 1.000   |
| CN (III–XII)        | 4 (33.3%)                 | 2 (16.7%)                 | 0.346   |
| Ataxia              | 6 (50%)                   | 1 (8.3%)                  | 0.025   |
| Sensory symptoms    | 3 (25%)                   | 0 (0%)                    | 0.064   |
| Bladder/rectum dysfunction | 2 (16.7%)   | 7 (58.3%)                 | 0.035   |
| paralysis           | 3 (25%)                   | 10 (83.3%)                | 0.004   |
| TM (symptom + MRI lesion) | 2 (16.7%)   | 7 (58.3%)                 | 0.035   |
| Prior infection     | 7 (58.3%)                 | 7 (58.3%)                 | 1.000   |
| ICU admission       | 3 (25%)                   | 3 (25%)                   | 1.000   |
| Period of hospital stay (days) | 16 (2.5–41.5) | 15 (3.5–33.5) | 0.772   |
| Time from symptom onset to immunotherapy (days) | 16 (0–58) | 8 (2–35) | 0.194   |
| Time from immunotherapy to improvement (days) | 7 (3–30) | 8 (4–30) | 0.794   |
| Time from immunotherapy to clinical recovery (days) |         |                           |         |
| ≤2 weeks            | 3 (25%)                   | 2 (16.7%)                 | 0.615   |
| 2–4 weeks           | 5 (41.7%)                 | 4 (33.3%)                 | 0.673   |
| 4 weeks ≤3 months   | 3 (25%)                   | 5 (41.7%)                 | 0.386   |
| ≥3 months           | 1 (8.3%)                  | 1 (8.3%)                  | 1.000   |
| Time from symptom onset to brain MRI (days) | 18.5 (6–33) | 11.5 (6–19) | 0.064   |
| Cerebrospinal fluid results |         |                           |         |
| Pleocytosis (WBC ≥ 5) | 10 (83.3%) | 9 (75%)                   | 0.615   |
| Increased protein concentrations(≥45 mg/dl) | 6 (50%) | 4 (33.3%) | 0.408   |
| Oligoclonal bands   | 2/8 (25%)                 | 0/7 (0%)                  | 0.004   |
| EEG results         |                           |                           |         |
| Slow background activity | 7 (58.3%) | 10 (83.3%) | 0.178   |
| Interictal epileptic paroxysms | 0 (0%) | 0 (0%) |         |
| Normal              | 5 (41.7%)                 | 2 (16.7%)                 | 0.178   |
| MRI areas affected  |                           |                           |         |
| Supratentorial white matter | 11 (91.7%) | 10 (83.3%) | 0.500   |
| Basal ganglia       | 11 (91.7%)                 | 10 (83.3%)                | 0.500   |
| Brainstem           | 9 (75.0%)                  | 4 (33.3%)                 | 0.050   |
| Cerebellar          | 7 (58.3%)                  | 2 (16.7%)                 | 0.045   |
| Spinal (LETM)       | 7 (58.3%)                  | 7 (58.3%)                 | 0.660   |
| Corpus callosum     | 4 (33.3%)                  | 2 (16.7%)                 | 0.320   |
| Typical brain MRI   | 11 (91.7%)                 | 8 (66.7%)                 | 0.158   |
| Brainstem/spinal lesions combined | 5 (41.7%) | 2 (16.7%) | 0.185   |
| mRS before immunotherapy |         |                           |         |
| mRS = 0             | 10 (83.3%)                 | 12 (100%)                 | 0.140   |
| mRS = 1–2           | 1 (8.3%)                   | 0 (0%)                    | 0.307   |
| mRS = 3–5           | 1 (8.3%)                   | 0 (0%)                    | 0.307   |
| mRS = 6             | 0 (0.0%)                   | 0 (0.0%)                  |         |
| Outcomes (mRS)      |                           |                           |         |
| mRS = 0             | 4 (2–5)                    | 5 (4–5)                   | 0.010   |
| mRS = 1–2           | 0 (0–4)                    | 0 (0–0)                   |         |
| mRS = 3–5           | 10 (83.3%)                 | 12 (100%)                 | 0.140   |
| mRS = 6             | 1 (8.3%)                   | 0 (0%)                    | 0.307   |
| Recurrence          | 0 (0.0%)                   | 0 (0.0%)                  |         |
| Follow-up (months)  | 20 (12–42)                 | 30 (12–48)                | 0.543   |

MOG, myelin oligodendrocyte glycoprotein; CN, cranial nerve; TM, transverse myelitis; ICU, intensive care unit; WBC, white blood cells; MRI, magnetic resonance imaging; EEG, electroencephalogram; ADEM, acute disseminating encephalomyelitis; LETM, longitudinally extensive transverse myelitis; LETM, longitudinal extensive transverse myelitis.
FIGURE 2 | Magnetic resonance imaging (MRI) results of pediatric acute disseminating encephalomyelitis (ADEM) with myelin oligodendrocyte glycoprotein antibodies (MOG-abs). (A–D) Cerebral MRI of a 6-year-old patient with MOG-abs, who presented with fever, headache, projectile vomiting, drowsiness, and ataxia, revealed large and blurred lesions involving both hemispheres [(A), axial-T2], corpus callosum, thalamus/basal ganglia [(B), axial-T2], brainstem, and cerebellum (not shown). 

(Continued)
at the last follow-up (mRS = 0); the other two (16.7%) children continued to have persistent neurological sequelae (one child had visual dysfunction, mRS = 1; one child had paralysis, mRS = 4). The only patient with an mRS of 4 at the last follow-up was a 1-year-old boy with MOG-abs who presented with fever and altered consciousness; he was admitted to the ICU. Cerebral MRI at the acute stage revealed a small and blurred supratentorial lesion, as well as lesions in the basal ganglia and brainstem. Three weeks later, a repeat cerebral MRI revealed diffuse cortical atrophy. By contrast, all children in the ADEM without MOG-abs group had a normal outcome at the last follow-up (mRS = 0). No recurrence was recorded at the last follow-up.

**DISCUSSION**

MOG is a glycoprotein located on the myelin surface and found exclusively in the CNS. In recent years, MOG-abs have been extensively studied. MOGAD is now recognized as a distinct nosological entity with specific clinical features, therapeutic requirements, and prognosis.

A nationwide study (11) in the Netherlands indicates that the overall incidence of MOG-IgG-seropositive disorders is 0.16 per 100,000 people, with a higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000), and the most common presenting phenotype is ADEM in children (56%) and ON in adults (44%). The onset phenotype in MOGAD varies with age (ADEM is more common in younger patients) but not with ethnicity or sex (14), and most MOGAD patients were Caucasian (15). To date, no nationwide study has been conducted regarding the incidence of MOGAD in China. A recent study (16), which included 25 Chinese pediatric MOGAD patients, revealed that Chinese children and Caucasians share the same clinical characteristics.

In this study, we compared the demographic and clinical characteristics, neuroimaging results, and outcomes of pediatric ADEM patients with and without MOG-abs based on the updated definition of ADEM by the IPMSSG.

Among children who were tested for MOG-abs in this study, 14 (42.4%) of 33 children were positive (Figure 1), which is in accordance with the results of a previous study (17) of Chinese children with relapsing anti-MOG-IgG-associated CNS demyelination. The median age at disease onset was 72 (range: 19–156) months, which conforms to a previous report of bimodal distribution of anti-MOG seropositivity in patients based on age of onset, with a higher prevalence of encephalopathy observed in the younger group (4–8 years old) and almost exclusively with ON in the older group (13–18 years) (18). An interesting finding was that children with MOG-abs presented with increased ataxia and less bladder/rectum dysfunction and paralysis at symptom onset compared to children without MOG-abs. Although 58.3% of patients in each group had abnormal spinal MRI findings, spinal dysfunction was only recorded in two patients with MOG-abs compared to seven patients without MOG-abs. This finding revealed that most spinal lesions in ADEM with MOG-abs group patients were subclinical. Otherwise, no significant differences existed in sex ratio, age at disease onset, follow-up period, previous infection, ICU admission, and period of hospital stay between the two groups.

Pleocytosis was recorded in 10 (83.3%) of 12 children with MOG-abs and nine (75%) of 12 children without MOG-abs. This finding revealed an inflammatory burden of the CNS in the acute phase that was independent of the anti-MOG-ab status. Previous studies (19) suggest that children with MOG-abs rarely have an OCB in contrast to children with multiple sclerosis (MS); however, our study showed a higher OCB rate in children with MOG-abs (2/8, 25%) than in children without MOG-abs (0/7, 0%). This finding has also been reported in previous studies (20, 21), revealing an intrathecal OCB rate ranging from 0 to 20%, which may have contributed to the different pathophysiology between MOGAD and other CNS demyelination.

Typical cerebral MRI lesions were detected in 11 (91.7%) children with MOG-abs and in eight (66.7%) children without MOG-abs, which is similar to what has been reported in previous studies. This finding suggests that children with anti-MOG-ab-associated ADEM have an increased rate of large, bilateral, and widespread lesions, particularly in the cerebral and spinal cord areas (6, 22). The most common locations of lesions in both groups were in the supratentorial white matter and thalamus/basal ganglia, which were consistent with the findings of a previous study conducted by Baumann et al. (23). Consistent with the clinical symptoms observed in our study, no significant difference existed in the number of lesions located in the cerebral and spinal regions between ADEM patients with and without MOG-abs apart from cerebellar lesions, which were more frequent in children with MOG-abs (7/12, 58.3%) than in children without MOG-abs (2/12, 16.7%). LETM was found in five (71.4%) of seven children with abnormal spinal MRI results in both groups, but an interesting finding was that spinal dysfunction accompanied by an abnormal spine MRI was significantly lower in children with MOG-abs (2/7, 28.6%) than in children without MOG-abs (7/7, 100%). This finding revealed that subclinical spine lesions occur in most pediatric...
FIGURE 3 | Magnetic resonance imaging (MRI) results of pediatric acute disseminating encephalomyelitis (ADEM) without anti-myelin oligodendrocyte glycoprotein antibodies (MOG-abs). (A–D) Cerebral MRI of a 3-year-old patient with ADEM but without MOG-abs who presented with frequent seizures and coma, revealed widespread, blurred, and large lesions involving supratentorial of both hemispheres and basal ganglia lesions [(A,B); axial-T2] similar to the typical cerebral MRI.
ADEM with MOG-obs patients, indicating the importance of screening for spinal cord lesions in patients without symptoms of myelopathy.

Consistent with previous findings, we detected a combination of brainstem and spinal lesions in five (71.4%) children with MOG-obs and two (16.7%) children without MOG-obs (4). An important factor is that the clinical symptoms and radiologic findings of ADEM can fluctuate in severity, as well as evolve, in the first 3 months following disease onset. For example, Duignan et al. (24) reported a radiological lag with worsening of the MRI results during clinical recovery in children with MOG-obs, which we also observed in children without MOG-obs in this study. Hence, conducting repeat MRI scans is important if typical MRI results are not revealed, which is in line with another study reporting that delayed abnormality was observed with MRI in seven of 13 ADEM cases (25). Contrary to previous studies (18) that did not detect any corpus callosum lesions in MOG-obs patients, four (33.3%) ADEM patients with MOG-obs and two (16.7%) patients without MOG-obs had corpus callosum lesions in this study, which was consistent with a previous study by Baumann et al. (23), who recorded corpus callosum lesions in 13 of 52 pediatric patients with MOG-obs-seropositive ADEM.

According to the updated recommended treatment approaches for MOGAD in children, first-line immunotherapy normally consists of intravenous corticosteroids, IVIG, and PE in isolation or combination (26). The prognosis of ADEM is typically favorable, and the complete recovery rate has been reported as between 57 and 92% in several pediatric cohorts of ADEM (27). Patients with MOG-obs and a monophasic disease course often have good clinical recovery and lesion resolution in the context of declining anti-MOG-obs MOG-obs (5). Compared to previous studies, the clinical outcomes in this study were evaluated relatively objectively through the use of mRS, which ensured the consistency of clinical evaluation by different clinicians.

A higher median mRS was recorded in the ADEM without MOG-obs group before immunotherapy; however, no significant difference existed between the groups during the last follow-up. Furthermore, the median time from immunotherapy to an improvement in clinical symptoms was 7 (range: 3–30) days and 8 (range: 4–30) days in the ADEM with MOG-obs and without MOG-obs groups, respectively, which is consistent with the findings of a previous study (27). This finding suggests that the progression of neurologic deficits in pediatric ADEM typically only lasts a few days, with the initial improvement occurring within 1 week, leading to a full recovery within 1 month. An important finding was most of the children in both groups attained clinical recovery within 3 months. Thus, 10 (83.3%) of 12 children in the ADEM with MOG-obs group and all of the children in the ADEM without MOG-obs group had a normal outcome at the last follow-up (mRS = 0). Two (16.7%) of 12 children with ADEM and MOG-obs unfortunately had persistent neurological sequelae (one patient had visual dysfunction, mRS = 1; one patient had paralysis, mRS = 4) compared to patients with full a recovery in the ADEM without MOG-obs group. However, serum MOG-obs were not retested in these two patients during follow-up, so it is impossible to elaborate the relationship between MOG-obs titers and clinical outcomes. Cerebral MRI of the ADEM patients with mRS 4 revealed diffused cortical atrophy, which suggested severe damage in the developing brain of an ADEM with MOG-obs patient. We are not the first team to observe this phenomenon because cases of a monophasic event and MOG-obs in children who experienced severe neurological sequelae such as tetraplegia, severe motor sequelae, and seizure have been previously reported (28).

An important finding that should be mentioned is that a 7-year-old boy with ADEM and negative for MOG-obs, who presented with fever, seizure, and altered consciousness, experienced improvements in the next year after immunotherapy and continuous medical rehabilitation. An exciting improvement was that he regained the ability to walk independently again 7 months after immunotherapy and experienced a full clinical recovery 1 year later. This outcome suggested that children with ADEM can experience sustained improvement even up to 1 year after immunotherapy.

Previous reports suggest that a monophasic illness accounts for most cases of ADEM with MOG-obs and is associated with male sex, a younger age at diagnosis (<10 years old), and pathology not involving the optic nerves (5, 6). Furthermore, studies suggest that most anti-MOG-obs seropositive children have a monophasic disease course, and in most children, the second demyelinating event occurs within the first year (10, 19, 29, 30). However, no recurrence occurred in our study during a median follow-up period of 20 months. This finding may be attributable to the prompt administration of immunotherapy, a younger age at diagnosis, and the lack of involvement of the optic
nerve, which suggested good clinical recovery of children with ADEM, regardless of anti-MOG-ab status.

The present study had several limitations. First, owing to its retrospective design, the accuracy of the clinical symptoms and time course were limited. Second, the sample size was smaller than that reported in previous studies of pediatric ADEM, thereby limiting translatability to the majority of the Chinese pediatric population. Third, fixed CBA was used to test for serum MOG-abs in this study, which may have missed some MOG-abs-positive patients for the lower reliability than live CBA (31). Therefore, future studies with larger sample sizes, longer follow-up periods, and multicenter cooperation are needed. Finally, evaluating the sensory symptoms and ataxia of patients with severe disturbances in consciousness or in younger patients is inaccurate and may lead to an underestimation of these symptoms.

CONCLUSIONS

Our study shows that MOG-abs-positive ADEM is a major subtype of pediatric ADEM. Ataxia is a common clinical manifestation in children with ADEM and MOG-abs. Children with ADEM and MOG-abs and children without MOG-abs have similar patterns of lesions, characterized by large, bilateral, and widespread lesions with a greater number of cerebellar lesions. Most spinal lesions were subclinical in pediatric ADEM with MOG-abs. Thus, spinal MRI is necessary in pediatric ADEM with MOG-abs, even in patients without clinical spinal dysfunction. Nevertheless, the overall clinical prognosis for most pediatric ADEM patients is good, but patients with MOG-abs are likely to have worse neurological sequela.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Children’s Hospital of Fudan University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

MZ and JS wrote the initial draft of the paper. YZ, LY, and WL collected the patients’ demographic and clinical data through medical records and telephone interviews. JS and LZ guided the analysis of neuroimaging results. SZ acted as the third rater in instances of discordant results. XD guided the statistical analysis of this study. LZ and YW guided the study design and made critical revisions to the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International pediatric multiple sclerosis study group. international pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. (2013) 19:1261–7. doi: 10.1177/1352458513484457
2. Leake JA, Albani S, Kao AS, Senac MO, Billman GF, Nespeca MP, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J. (2004) 23:756–64. doi: 10.1097/01.inf.0000133048.75452.dd
3. Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. (2009) 72:232–39. doi: 10.1212/01.wnl.0000339482.84392.bd
4. Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. (2015) 86:265–72. doi: 10.1136/jnnp-2014-308346
5. Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. (2017) 89:900–8. doi: 10.1212/WNL.0000000000004312
6. Baumann M, Hennes EM, Schanda K, Karenfort M, Kornek B, Seidl R, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler. (2016) 22:1821–9. doi: 10.1177/1352458516631038

7. Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. (2012) 69:752–6. doi: 10.1001/archneur.2011.2956
8. Huppke P, Rostasy K, Karenfort M, Huppke B, Seidl R, Leiz S, et al. Disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler. (2013) 19:941–6. doi: 10.1177/1352458512466317
9. Sepúlveda M, Armanuqe T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. Clinical spectrum associated with MOG autoimmunity in adults. J Neurol. (2016) 263:1349–60. doi: 10.1007/s00415-016-8147-7
10. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neuro. (2014) 71:276–83. doi: 10.1001/jamaneurol.2013.5857
11. de Mol CL, Wong YYM, van Pelt ED, Wokke BHA, Siepman TAM, Neuteboom RF, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. (2020) 26:806–14. doi: 10.1177/1352458519845112
12. Zhang M, Li W, Zhou S, Zhou Y, Yang H, Yu L, et al. Clinical features, treatment, and outcomes among Chinese children with anti-methyl-d-aspartate receptor (Anti-NMDAR) encephalitis. Front Neurol. (2019) 10:596. doi: 10.3389/fneur.2019.00596
13. Verhey LH, Branson HM, Shroff MM, Callen DJ, Sled JG, Narayanan S, et al. Canadian pediatric demyelinating disease network. mri parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol. (2011) 10:1065–73. doi: 10.1016/S1474-4422(11)70250-2
24. Duignan S, Messina S, Woodhall MR, Raza N, Everett R, Fernandez AR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Front Neurol. (2017) 8:312. doi: 10.3389/fneur.2017.00312

25. Khurana DS, Melvin JJ, Kothe SV, Valencia I, Hardison HH, Yum S, et al. Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics. (2005) 116:431–6. doi: 10.1542/peds.2004-2038

26. Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol. (2019) 21:2. doi: 10.1007/s11940-019-0541-x

27. Nishiyama M, Nagase H, Tomioka K, Tanaka T, Yamaguchi H, Ishida Y, et al. Clinical time course of pediatric acute disseminated encephalomyelitis. Brain Dev. (2019) 41:531–7. doi: 10.1016/j.braindev.2019.02.011

28. Lechner C, Baumann M, Hennes EM, Schanda K, Marquard K, Karenfort M, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry. (2016) 87:897–905. doi: 10.1136/jnnp-2015-317743

29. Taghdiri MM, Amouzadeh MH, Esmail Nejad SS, Abasi E, Alipour A, Akhavan Sepahi M. Epidemiological, clinical, and laboratory characteristics of acute disseminated encephalomyelitis in children: a retrospective study. Iran J Child Neurol. (2019) 13:65–73.

30. Cole J, Evans E, Mwangi M, Mar S. Acute disseminated encephalomyelitis in children: an updated review based on current diagnostic criteria. Pediatr Neurol. (2019) 109:26–34. doi: 10.1016/j.peditrneurol.2019.06.017

31. Gastaldi M, Scaranzin S, Jarius S, Wildeman B, Zardini E, Mallucci G, et al. Cell-based assays for the detection of MOG antibodies: a comparative study. J Neurol. (2020). doi: 10.1007/s00415-020-10024-0. [Epub ahead of print].

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zhang, Shen, Zhou, Du, Li, Yu, Zhang, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.